Hemopurifier.jpg
Location data
Loading map...
Location California, United States


Medical equipment data
Health topic HIV/AIDS
Health classification Treatment
Project data
Status Clinical trial
Made? No
Replicated? No
Export to Open Know How Manifest
Page data
Part of Global Health Medical Device Compendium
Type Medical equipment, Project
SDGs Sustainable Development Goals SDG03 Good health and well-being
SDG09 Industry
innovation and infrastructure
Authors Evashiu
Published 2012
License CC BY-SA 3.0
Language English (en)
Page views 920


Problem being addressed[edit | edit source]

The Hemopurifier™ has been developed to address the treatment of drug and vaccine-resistant pathogens, including Ebola & HIV which causes AIDS.

Detailed description of the solution[edit | edit source]

The Hemopurifier™ is a dialysis-type medical device designed to mimic the natural immune response of clearing infectious viruses and toxins before the occurrence of cell and organ infection. Human in-vitro blood studies have documented a rapid capture of circulating HIV and gp120, a toxic surface protein known to deplete the immune T-cells required to fight off infection. If commercialized, the Hemopurifier™ would represent the first medical device enlisted as a treatment for HIV/AIDS.

Designed by[edit | edit source]

  • Design: Aethlon Medical, Inc.
  • Manufacturer Location: San Diego, California, USA

When and where it was tested/implemented[edit | edit source]

Testing has been done in the United States since 2001. It is currently being tested in human clinical trials in India.

Funding Source[edit | edit source]

Private Funding

References[edit | edit source]

Peer-reviewed publication[edit | edit source]

Duffin, R.P. & Tullis, R.H. (2002). Mathematical models that predict the complete course of HIV infection and AIDS. J. Theor. Med, 4(3), 157-166.

Tullis, R.H., Ambrus, J.L. & Joyce, J.A. (2001). Affinity Hemodialysis as a Treatment for AIDS. American Clinical Laboratories, Oct/Nov, 22-23.

Tullis, R.H., Duffin, R.P., Zech, M. & Ambrus, J.L. (2001). Affinity Hemodialysis for Antiviral Therapy. I. Removal of HIV-1 from Cell Culture Supernatants, Plasma and Blood. Therapeutic Apheresis, 6 (3), 213-220.

Tullis, R.H., Scammura, D.O. & Ambrus, J.L. (2002). Affinity Hemodialysis for Antiviral Therapy with Specific Application to HIV. J. Theor Med, 3(2002), 157-166.

Tullis, R.H., Duffin, R.P., Zech, M. & Ambrus, J.L. (2003). Affinity hemodialysis for antiviral therapy. II. Removal of HIV-1 viral proteins from cell culture supernatants and whole blood. Blood Purification, 21(1), 58-64.

Approval by regulatory bodies or standards boards[edit | edit source]

An investigational device exemption (IDE) to initiate clinical studies in the United States is pending with the Food and Drug Administration.